Related Experiment Video
Updated: Aug 6, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic
Hyun S Kim1, Ajanta Patra, Ben E Paxton
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 545, Baltimore, MD 21287-4010, USA. sikhkim@jhmi.edu
Insights
Catheter-directed thrombolysis (CDT) with percutaneous mechanical thrombectomy (PMT) is as effective as CDT alone for lower-extremity deep vein thrombosis (DVT). This combined approach reduces treatment time and costs, offering a more efficient treatment option.
Area of Science:
- Vascular Surgery
- Interventional Radiology
- Thrombosis Management
Background:
- Deep vein thrombosis (DVT) is a significant cause of morbidity and mortality.
- Catheter-directed thrombolysis (CDT) is a common treatment for extensive DVT.
- Optimizing CDT protocols to improve efficacy and reduce costs is crucial.
Purpose of the Study:
- To compare the clinical and economic outcomes of CDT alone versus CDT combined with rheolytic percutaneous mechanical thrombectomy (PMT).
- To evaluate the effectiveness and cost-efficiency of pharmacomechanical thrombolysis for acute iliofemoral DVT.
Main Methods:
- A retrospective analysis of consecutive patients with acute iliofemoral DVT treated between 1997 and 2003.
- Patients received either CDT with urokinase alone or CDT with urokinase plus PMT.
- Clinical outcomes (lysis rates, bleeding, PE) and economic outcomes (costs) were compared.
Main Results:
- CDT plus PMT demonstrated significantly shorter treatment durations (30.3 vs 56.5 hours) and lower urokinase doses (2.95 vs 6.70 million U).
- Complete clot lysis rates were similar between the two groups (84.2% vs 80.7%).
- Major bleeding and pulmonary embolism rates were comparable; however, CDT plus PMT resulted in significantly lower costs ($5,128 vs $10,127).
Conclusions:
- Percutaneous CDT with rheolytic PMT is a safe and effective alternative to CDT alone for acute iliofemoral DVT.
- Pharmacomechanical thrombolysis offers reduced treatment time, lower drug utilization, and decreased costs.
- Further randomized trials are recommended to validate these findings for DVT treatment.
Purpose:
To assess the clinical and economic benefits of catheter-directed thrombolysis (CDT) alone versus CDT with rheolytic percutaneous mechanical thrombectomy (PMT) for lower-extremity deep vein thrombosis (DVT).
Materials And Methods:
Consecutive patients with acute iliofemoral DVT treated with CDT with urokinase between 1997 and 2003 were identified. Demographic characteristics and clinical and economic outcomes were compared between patients treated with CDT alone versus CDT plus PMT.
Results:
Twenty-six limbs in 23 patients received CDT with urokinase, whereas 19 limbs in 14 patients were treated with CDT plus PMT. Mean treatment duration for CDT was 56.5 +/- 27.4 hours, compared with 30.3 +/- 17.8 hours for CDT plus PMT (P = .001). Mean urokinase dose for CDT was 6.70 +/- 5.9 million U compared with 2.95 +/- 1.82 million U for CDT plus PMT (P = .011). Urokinase CDT achieved complete clot lysis in 80.7% of limbs (n = 21) compared with 84.2% of limbs (n = 16) treated with CDT plus PMT (P = .764). The incidences of major bleeding (CDT, 7.7%; CDT plus PMT, 5.3%; P = .749) and pulmonary embolism (CDT, 3.8%; CDT plus PMT, 5.3%; P = .818) were similar. The mean urokinase and PMT device cost for CDT alone was $10,127 compared with $5,128 for CDT plus PMT (P = .026).
Conclusions:
Percutaneous CDT with rheolytic PMT is as effective as CDT alone for acute iliofemoral DVT but requires significantly shorter treatment and lower lytic agent dose, resulting in lower costs. Randomized studies to confirm the benefits of pharmacomechanical thrombolysis in the treatment of DVT are warranted.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Peripheral Artery Disease III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management